{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:11:48Z","timestamp":1790014308554,"version":"4.0.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes &amp; Diseases"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.gendis.2025.102026","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T15:54:27Z","timestamp":1767455667000},"page":"102026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Perspectives of EGFR co-targeting with nanocarriers for anti-TNBC purposes"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-0175","authenticated-orcid":false,"given":"Piotr","family":"Bia\u0142ecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi\u0142osz","family":"Adamiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"P\u0119dziwiatr-Werbicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6265-5585","authenticated-orcid":false,"given":"Agnieszka","family":"Robaszkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"29","key":"10.1016\/j.gendis.2025.102026_bib1","doi-asserted-by":"crossref","first-page":"26560","DOI":"10.18632\/oncotarget.5306","article-title":"Triple negative breast cancer: looking for the missing link between biology and treatments","volume":"6","author":"Palma","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.gendis.2025.102026_bib2","first-page":"1609","article-title":"A perspective on anti-EGFR therapies targeting triple-negative breast cancer","volume":"6","author":"Nakai","year":"2016","journal-title":"Am J Cancer Res"},{"issue":"7418","key":"10.1016\/j.gendis.2025.102026_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.gendis.2025.102026_bib4","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.14694\/EdBook_AM.2015.35.e31","article-title":"Triple-negative breast cancer: molecular subtypes and new targets for therapy","author":"Lehmann","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1016\/j.gendis.2025.102026_bib5","first-page":"6562","article-title":"Breast cancers with EGFR and HER2 co-amplification favor distant metastasis and poor clinical outcome","volume":"14","author":"Guo","year":"2017","journal-title":"Oncol Lett"},{"issue":"13","key":"10.1016\/j.gendis.2025.102026_bib6","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/1078-0432.CCR-22-0283","article-title":"Molecular pathways and mechanisms of HER2 in cancer therapy","volume":"29","author":"Raghav","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.gendis.2025.102026_bib7","article-title":"EGFR-directed antibodies promote HER2 ADC internalization and efficacy","volume":"5","author":"Gupta","year":"2024","journal-title":"Cell Rep Med"},{"issue":"12","key":"10.1016\/j.gendis.2025.102026_bib8","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3390\/cancers11121826","article-title":"Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials","volume":"11","author":"Maennling","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.gendis.2025.102026_bib9","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.5604\/17322693.1077713","article-title":"Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches","volume":"67","author":"Nowacka-Zawisza","year":"2013","journal-title":"Postepy Hig Med Dosw (Online)"},{"issue":"2","key":"10.1016\/j.gendis.2025.102026_bib10","first-page":"106","article-title":"Current approaches in treatment of triple-negative breast cancer","volume":"12","author":"Wahba","year":"2015","journal-title":"Cancer Biol Med"},{"issue":"11","key":"10.1016\/j.gendis.2025.102026_bib11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.gendis.2025.102026_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5306\/wjco.v12.i3.164","article-title":"Overview of recent advances in metastatic triple negative breast cancer","volume":"12","author":"O\u2019Reilly","year":"2021","journal-title":"World J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2025.102026_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.annonc.2020.10.471","article-title":"Neoadjuvant paclitaxel\/olaparib in comparison to paclitaxel\/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)","volume":"32","author":"Fasching","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.gendis.2025.102026_bib14","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.gendis.2025.102026_bib15","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","article-title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis","volume":"29","author":"Poggio","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.gendis.2025.102026_bib16","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.31557\/APJCP.2024.25.3.1025","article-title":"Prognostic values of CD8+, PARP, and EGFR on overall survival in patients with triple-negative breast cancer","volume":"25","author":"Putri","year":"2024","journal-title":"Asian Pac J Cancer Prev"},{"issue":"24","key":"10.1016\/j.gendis.2025.102026_bib17","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-06-0626","article-title":"Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response","volume":"12","author":"Brandt","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.gendis.2025.102026_bib18","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s11523-020-00753-7","article-title":"Cetuximab in patients with breast cancer, non-small cell lung cancer, and ovarian cancer without KRAS, NRAS, or BRAF mutations: results from the targeted agent and profiling utilization registry (TAPUR) study","volume":"15","author":"Fisher","year":"2020","journal-title":"Target Oncol"},{"issue":"5","key":"10.1016\/j.gendis.2025.102026_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1135","article-title":"EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo","volume":"9","author":"Xia","year":"2020","journal-title":"Clin Transl Immunol"},{"issue":"4","key":"10.1016\/j.gendis.2025.102026_bib20","article-title":"An engineering strategy to target activated EGFR with CAR T cells","volume":"4","author":"Dobersberger","year":"2024","journal-title":"Cell Rep Methods"},{"issue":"1","key":"10.1016\/j.gendis.2025.102026_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol Oncol"},{"issue":"2","key":"10.1016\/j.gendis.2025.102026_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10549-012-2289-9","article-title":"Role of epidermal growth factor receptor in breast cancer","volume":"136","author":"Masuda","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.gendis.2025.102026_bib23","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1158\/0008-5472.CAN-15-2478","article-title":"EGFR signaling enhances aerobic glycolysis in triple-negative breast cancer cells to promote tumor growth and immune escape","volume":"76","author":"Lim","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.102026_bib24","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1038\/s41467-023-38115-2","article-title":"TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression","volume":"14","author":"Bi","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.gendis.2025.102026_bib25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12943-024-02150-4","article-title":"Tumor-intrinsic role of ICAM-1 in driving metastatic progression of triple-negative breast cancer through direct interaction with EGFR","volume":"23","author":"Kang","year":"2024","journal-title":"Mol Cancer"},{"issue":"8","key":"10.1016\/j.gendis.2025.102026_bib26","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/modpathol.3800438","article-title":"EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations","volume":"18","author":"Bhargava","year":"2005","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.gendis.2025.102026_bib27","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nsmb.3074","article-title":"Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6","volume":"22","author":"Park","year":"2015","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.gendis.2025.102026_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/546318","article-title":"The role of epidermal growth factor receptor in cancer metastasis and microenvironment","volume":"2013","author":"Sasaki","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.gendis.2025.102026_bib29","article-title":"The paradoxical functions of EGFR during breast cancer progression","volume":"2","author":"Ali","year":"2017","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.gendis.2025.102026_bib30","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1186\/s12885-022-10390-0","article-title":"Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non-small-cell lung cancer patients: a prospective observational study","volume":"22","author":"Peng","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2025.102026_bib31","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.gendis.2025.102026_bib32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fonc.2015.00005","article-title":"Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma","volume":"5","author":"Padfield","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.gendis.2025.102026_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/15330338241234780","article-title":"Targeting receptor tyrosine kinases as a novel strategy for the treatment of triple-negative breast cancer","volume":"23","author":"Jaradat","year":"2024","journal-title":"Technol Cancer Res Treat"},{"issue":"23","key":"10.1016\/j.gendis.2025.102026_bib34","doi-asserted-by":"crossref","first-page":"27513","DOI":"10.1021\/acsami.1c07662","article-title":"Cationic polyporphyrins as siRNA delivery vectors for photodynamic and gene synergistic anti-cancer therapy","volume":"13","author":"Zheng","year":"2021","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.gendis.2025.102026_bib35","unstructured":"National Center for biotechnology information F fatty acid binding protein 4. Accessed 13 March 2023. https:\/\/www.ncbi.nlm.nih.gov\/gene\/2167"},{"key":"10.1016\/j.gendis.2025.102026_bib36","article-title":"Therapeutic implications of FABP4 in cancer: an emerging target to tackle cancer","volume":"13","author":"Sun","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.gendis.2025.102026_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217271","article-title":"FABP4-mediated lipid metabolism promotes TNBC progression and breast cancer stem cell activity","volume":"604","author":"Yu","year":"2024","journal-title":"Cancer Lett"},{"issue":"24","key":"10.1016\/j.gendis.2025.102026_bib38","doi-asserted-by":"crossref","first-page":"9739","DOI":"10.3390\/ijms21249739","article-title":"The roles of matrix metalloproteinases and their inhibitors in human diseases","volume":"21","author":"Cabral-Pacheco","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.gendis.2025.102026_bib39","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10549-020-05670-x","article-title":"Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival","volume":"182","author":"Joseph","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.gendis.2025.102026_bib40","article-title":"Combined knockdown of CD151 and MMP9 may inhibit the malignant biological behaviours of triple-negative breast cancer through the GSK-3\u03b2\/\u03b2-catenin-related pathway","volume":"14","author":"Li","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.gendis.2025.102026_bib41","first-page":"5020","article-title":"Association of BCSC-1 and MMP-14 with human breast cancer","volume":"15","author":"Di","year":"2018","journal-title":"Oncol Lett"},{"issue":"35","key":"10.1016\/j.gendis.2025.102026_bib42","doi-asserted-by":"crossref","first-page":"58372","DOI":"10.18632\/oncotarget.17702","article-title":"A novel immunotherapy targeting MMP-14 limits hypoxia, immune suppression and metastasis in triple-negative breast cancer models","volume":"8","author":"Ling","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.gendis.2025.102026_bib43","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3390\/cancers11071039","article-title":"In vivo assessment of VCAM-1 expression by SPECT\/CT imaging in mice models of human triple negative breast cancer","volume":"11","author":"Montemagno","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.gendis.2025.102026_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-2744-0_1","article-title":"CCN proteins (cellular communication network factors): expanding their repertoire toward a new concept","volume":"2582","author":"Takigawa","year":"2023","journal-title":"Methods Mol Biol"},{"issue":"6","key":"10.1016\/j.gendis.2025.102026_bib45","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.3390\/curroncol28060417","article-title":"Potential role of CCN proteins in breast cancer: therapeutic advances and perspectives","volume":"28","author":"Ahmed","year":"2021","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.gendis.2025.102026_bib46","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.celrep.2013.03.027","article-title":"The protein interaction landscape of the human CMGC kinase group","volume":"3","author":"Varjosalo","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.gendis.2025.102026_bib47","unstructured":"GeneCards. CGCDK 6. Accessed 10 April 2025. https:\/\/www.genecards.org\/cgi-bin\/carddisp.plgene=CDK6"},{"issue":"5","key":"10.1016\/j.gendis.2025.102026_bib48","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1634\/theoncologist.2014-0443","article-title":"The role of CDK4\/6 inhibition in breast cancer","volume":"20","author":"Murphy","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.gendis.2025.102026_bib49","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.2147\/CMAR.S310649","article-title":"Potential prospect of CDK4\/6 inhibitors in triple-negative breast cancer","volume":"13","author":"Hu","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"5","key":"10.1016\/j.gendis.2025.102026_bib50","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.gendis.2025.102026_bib51","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/d41573-024-00064-w","article-title":"The antibody-drug conjugate landscape","volume":"23","author":"Flynn","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.gendis.2025.102026_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2009.03992.x","article-title":"Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy","volume":"158","author":"Martinelli","year":"2009","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2025.102026_bib53","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1038\/s41598-023-30950-z","article-title":"A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer","volume":"13","author":"Mamot","year":"2023","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.gendis.2025.102026_bib54","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3390\/pharmaceutics15030915","article-title":"DOPE\/CHEMS-based EGFR-targeted immunoliposomes for docetaxel delivery: formulation development, physicochemical characterization and biological evaluation on prostate cancer cells","volume":"15","author":"da Silva Moreira","year":"2023","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.gendis.2025.102026_bib55","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3390\/cancers13112748","article-title":"EGFR in cancer: signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.gendis.2025.102026_bib56","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2174\/0929867327666200130101605","article-title":"Nanoparticles in combating cancer: opportunities and limitations. A brief review","volume":"28","author":"Pedziwiatr-Werbicka","year":"2021","journal-title":"Curr Med Chem"},{"issue":"1","key":"10.1016\/j.gendis.2025.102026_bib57","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/molecules25010112","article-title":"The history of nanoscience and nanotechnology: from chemical-physical applications to nanomedicine","volume":"25","author":"Bayda","year":"2019","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.gendis.2025.102026_bib58","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/1556-276X-9-247","article-title":"Dendrimers: synthesis, applications, and properties","volume":"9","author":"Abbasi","year":"2014","journal-title":"Nanoscale Res Lett"},{"issue":"22","key":"10.1016\/j.gendis.2025.102026_bib59","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.3390\/polym15224369","article-title":"Dendrimers: exploring their wide structural variety and applications","volume":"15","author":"P\u00e9rez-Ferreiro","year":"2023","journal-title":"Polymers"},{"issue":"7","key":"10.1016\/j.gendis.2025.102026_bib60","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.3390\/ijms24076638","article-title":"Pegylated gold nanoparticles conjugated with siRNA: complexes formation and cytotoxicity","volume":"24","author":"Ok\u0142a","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.gendis.2025.102026_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09394","article-title":"Liposomes: structure, composition, types, and clinical applications","volume":"8","author":"Nsairat","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.gendis.2025.102026_bib62","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/8608428","article-title":"An overview of supramolecular platforms boosting drug delivery","volume":"2023","author":"Bellavita","year":"2023","journal-title":"Bioinorg Chem Appl"},{"key":"10.1016\/j.gendis.2025.102026_bib63","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fphar.2018.00080","article-title":"Advantages and limitations of current imaging techniques for characterizing liposome morphology","volume":"9","author":"Robson","year":"2018","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.gendis.2025.102026_bib64","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1007\/s00432-022-04189-6","article-title":"Triple negative breast cancer: approved treatment options and their mechanisms of action","volume":"149","author":"Mandapati","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2025.102026_bib65","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.yaoo.2023.02.012","article-title":"Ocular toxicity of immunotherapy and targeted antineoplastic agents","volume":"8","author":"Worley","year":"2023","journal-title":"Adv Ophthalmol Optom"},{"key":"10.1016\/j.gendis.2025.102026_bib66","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.1016\/j.gendis.2025.102026_bib67","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1021\/mp400212v","article-title":"Inhibition of tumor growth by targeted anti-EGFR\/IGF-1R nanobullets depends on efficient blocking of cell survival pathways","volume":"10","author":"van der Meel","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.gendis.2025.102026_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117119","article-title":"Non-viral vectors combined delivery of siRNA and anti-cancer drugs to reverse tumor multidrug resistance","volume":"178","author":"Xue","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.gendis.2025.102026_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.139219","article-title":"Shielding siRNA by peptide-based nanofibers: an efficient approach for turning off EGFR gene in breast cancer","volume":"292","author":"Bellavita","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.gendis.2025.102026_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174178","article-title":"siRNA: mechanism of action, challenges, and therapeutic approaches","volume":"905","author":"Alshaer","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.gendis.2025.102026_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120835","article-title":"Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer","volume":"605","author":"Chadar","year":"2021","journal-title":"Int J Pharm"},{"issue":"8","key":"10.1016\/j.gendis.2025.102026_bib72","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1109\/TNB.2016.2621730","article-title":"Nanoparticles for siRNA-based gene silencing in tumor therapy","volume":"15","author":"Babu","year":"2016","journal-title":"IEEE Trans Nanobioscience"},{"key":"10.1016\/j.gendis.2025.102026_bib73","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biomaterials.2019.04.020","article-title":"Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo","volume":"209","author":"Kozielski","year":"2019","journal-title":"Biomaterials"},{"issue":"21","key":"10.1016\/j.gendis.2025.102026_bib74","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.18632\/oncotarget.26747","article-title":"Dual inhibition of ABCE1 and LCP1 by microRNA-96 results in an additive effect in breast cancer mouse model","volume":"10","author":"Pillar","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.gendis.2025.102026_bib75","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.2147\/IJN.S161932","article-title":"Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles","volume":"13","author":"Kim","year":"2018","journal-title":"Int J Nanomedicine"},{"issue":"11","key":"10.1016\/j.gendis.2025.102026_bib76","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.3390\/biomedicines10112906","article-title":"TNBC therapeutics based on combination of fusarochromanone with EGFR inhibitors","volume":"10","author":"Carroll","year":"2022","journal-title":"Biomedicines"}],"container-title":["Genes &amp; Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235230422500515X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235230422500515X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:42:45Z","timestamp":1790012565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235230422500515X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S235230422500515X"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2025.102026","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perspectives of EGFR co-targeting with nanocarriers for anti-TNBC purposes","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2025.102026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102026"}}